<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822458</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-01180</org_study_id>
    <secondary_id>NCI-2009-01180</secondary_id>
    <secondary_id>CDR0000631677</secondary_id>
    <secondary_id>PBTC-025</secondary_id>
    <secondary_id>PBTC-025</secondary_id>
    <secondary_id>U01CA081457</secondary_id>
    <nct_id>NCT00822458</nct_id>
  </id_info>
  <brief_title>GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment</brief_title>
  <official_title>A Phase I Pharmacokinetic and Safety Study in Children With Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of GDC-0449 in treating young&#xD;
      patients with medulloblastoma that is recurrent or did not respond to previous treatment.&#xD;
      GDC-0449 may be effective in treating young patients with medulloblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To investigate the safety and pharmacokinetics of a daily dose of hedgehog antagonist&#xD;
      GDC-0449 using the available formulation in pediatric patients with recurrent or refractory&#xD;
      medulloblastoma.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To document and describe toxicities associated with this drug in these patients.&#xD;
&#xD;
      II. To characterize the pharmacokinetics of this drug in these patients. III. To document&#xD;
      preliminary antitumor activity of this drug in these patients. IV. To document pathologic and&#xD;
      genomic methods to identify CNS tumors with activation of the PTCH/SHH pathway.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral hedgehog antagonist GDC-0449 once daily on days 1 and 4-28 in course 1&#xD;
      and on days 1-28 in all subsequent courses. Treatment repeats every 28 days for up to 26&#xD;
      courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood samples are collected periodically for pharmacokinetic studies. Archival tumor tissue&#xD;
      samples are collected and analyzed for the expression of genes that activate the SHH (e.g.,&#xD;
      Gli1, Gli2, SFRP1, ATOH1, and PTCH2) or WNT (e.g., DKK2 and DKK4) cell signal pathways by in&#xD;
      situ hybridization and reverse transcriptase real time-PCR.&#xD;
&#xD;
      After completion of study therapy, patients are followed for 90 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean steady-state total (protein bound and non-protein bound) GDC-0449 plasma concentrations (Css)</measure>
    <time_frame>21 days</time_frame>
    <description>95% confidence interval estimates for 2 doses compared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of GDC-0449, including the elimination rate constant and terminal half life</measure>
    <time_frame>Up to 3 months after completion of study treatment</time_frame>
    <description>We will study two BSA defined strata.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor responses</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Descriptive statistics will be provided describing tumor responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Kaplan-Meier estimates of the distribution of progression-free survival (PFS) will be constructed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Recurrent Childhood Medulloblastoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral hedgehog antagonist GDC-0449 once daily on days 1 and 4-28 in course 1 and on days 1-28 in all subsequent courses. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Blood samples are collected periodically for pharmacokinetic studies. Archival tumor tissue samples are collected and analyzed for the expression of genes that activate the SHH (e.g., Gli1, Gli2, SFRP1, ATOH1, and PTCH2) or WNT (e.g., DKK2 and DKK4) cell signal pathways by in situ hybridization and reverse transcriptase real time-PCR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vismodegib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Erivedge</other_name>
    <other_name>GDC-0449</other_name>
    <other_name>Hedgehog antagonist GDC-0449</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed medulloblastoma, including posterior fossa primitive&#xD;
             neuroectodermal tumor (PNET)&#xD;
&#xD;
          -  Recurrent, progressive, or refractory to standard therapy&#xD;
&#xD;
          -  No known curative therapy exists&#xD;
&#xD;
          -  Neurological deficits allowed provided they are stable for ≥ 1 week prior to study&#xD;
             entry&#xD;
&#xD;
          -  No atypical teratoid/rhabdoid tumor or supratentorial PNET&#xD;
&#xD;
          -  Karnofsky performance status (PS) 60-100% (for patients &gt; 16 years of age) OR Lansky&#xD;
             PS 60-100% (for patients ≤ 16 years of age)&#xD;
&#xD;
          -  ANC ≥ 1,000/μL*&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL (transfusion independent)*&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL (RBC transfusion allowed)*&#xD;
&#xD;
          -  Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on age&#xD;
             as follows:&#xD;
&#xD;
               -  ≤ 0.8 mg/dL (for patients ≤ 5 years of age)&#xD;
&#xD;
               -  ≤ 1.0 mg/dL (for patients 6 to 10 years of age)&#xD;
&#xD;
               -  ≤ 1.2 mg/dL (for patients 11 to 15 years of age)&#xD;
&#xD;
               -  ≤ 1.5 mg/dL (for patients &gt; 15 years of age)&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age&#xD;
&#xD;
          -  ALT/AST ≤ 2.5 times ULN for age&#xD;
&#xD;
          -  Serum albumin ≥ 2.5 g/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile female patients must use 2 effective methods of contraception during and for&#xD;
             12 months following study treatment&#xD;
&#xD;
          -  Fertile male patients must use effective barrier contraception during and for 12&#xD;
             months following study treatment&#xD;
&#xD;
          -  Body surface area &gt; 0.67 m^2 and ≤ 2.5 m^2&#xD;
&#xD;
          -  Able to swallow capsules&#xD;
&#xD;
          -  No malabsorption syndrome or other condition that would interfere with enteral&#xD;
             absorption&#xD;
&#xD;
          -  No history of congestive heart failure&#xD;
&#xD;
          -  No history of ventricular arrhythmia requiring medication&#xD;
&#xD;
          -  No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, or hypokalemia, defined as&#xD;
             less than the lower limit of normal despite adequate electrolyte supplementation&#xD;
&#xD;
          -  No clinically important history of liver disease, including viral hepatitis or&#xD;
             cirrhosis&#xD;
&#xD;
          -  No concurrent clinically significant unrelated systemic illness (e.g., serious&#xD;
             infection) or significant cardiac, pulmonary, hepatic, or other organ dysfunction that&#xD;
             would compromise the patient's ability to tolerate study treatment or would likely&#xD;
             interfere with study procedures or results&#xD;
&#xD;
               -  NOTE: * In the absence of bone marrow involvement&#xD;
&#xD;
          -  Recovered from prior treatment-related toxicity&#xD;
&#xD;
          -  At least 3 months since prior craniospinal radiotherapy (at doses ≥ 23 Gy)&#xD;
&#xD;
          -  At least 8 weeks since prior local radiotherapy to primary tumor&#xD;
&#xD;
          -  At least 2 weeks since prior focal radiotherapy to symptomatic metastatic sites&#xD;
&#xD;
          -  More than 4 weeks since prior myelosuppressive chemotherapy or immunotherapy (6 weeks&#xD;
             for nitrosoureas)&#xD;
&#xD;
          -  More than 1 week since prior colony-stimulating factors (e.g., filgrastim [G-CSF],&#xD;
             sargramostim [GM-CSF], or erythropoietin)&#xD;
&#xD;
          -  No other concurrent anticancer or investigational drug therapy&#xD;
&#xD;
          -  Concurrent dexamethasone allowed provided dosage is stable or decreasing for ≥ 1 week&#xD;
             prior to study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amar Gajjar</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Brain Tumor Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF-Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Brain Tumor Consortium</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2009</study_first_posted>
  <last_update_submitted>April 1, 2014</last_update_submitted>
  <last_update_submitted_qc>April 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medulloblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

